Research programme: complement system inhibitors- Bioverativ

Drug Profile

Research programme: complement system inhibitors- Bioverativ

Alternative Names: BIVV-020; TNT 010; TNT 020

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ
  • Class Monoclonal antibodies
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 28 Jun 2017 True North Therapeutics has been acquired and merged into Bioverativ
  • 15 Dec 2015 Preclinical trials in Undefined indication in USA (Parenteral) (True North Therapeutics pipeline; December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top